

# Colorectal Cancer in Focus

Patient and Healthcare Provider Perspectives on Advancing Treatment

*National Survey of Healthcare Providers and Patients Underscores Gaps in Standard Care and a Strong Demand for New Therapies*


Despite advances in screening and treatment, current therapies remain ineffective for approximately 95% of individuals with colorectal cancer (CRC). Standard care typically includes surgery, chemotherapy, and radiation, yet significant gaps remain. In recent years, immunotherapy has emerged as a promising approach, highlighting the need for continued innovation in CRC treatment.

## Key Survey Findings

**AgenuS** set out to better understand patient and health care provider (HCP) perspectives on advancing treatments for CRC. We surveyed **126 patients** living with colorectal cancer and **100 healthcare providers** who treat patients with CRC to better understand their perspectives on advancing treatments.

### Early-onset CRC is on The Rise

Consistent with recent data, early-onset CRC (EOCRC) is on the rise, highlighting the need for greater awareness, early detection, and tailored treatment approaches.



**89%** of HCPs are seeing CRC rates climbing among adults under 50



**82%** of Patient Respondents were under 50 years of age when diagnosed




I am 43 and had no symptoms at all. I wish there was more education for younger people.

—Individual living with CRC

### Gaps in the Standard of Care

Despite advances in treatment, significant challenges remain in effectively managing colorectal cancer, emphasizing the need for new and improved options.



**93%** of HCPs believe current treatment options for CRC are insufficient



**More than 2/3** of HCPs agree there is a need for newer treatment options beyond chemo and current immuno-oncology

### Demand for Chemotherapy Alternatives

Many patients are seeking alternatives to chemotherapy, reinforcing the importance of expanding access to innovative treatment approaches.




**97% of HCPs** respondents said they are asked by their patients with CRC about alternative treatment options to chemotherapy to at least some degree.

#### Majority of patients highly value the possibility of a CRC treatment that does not involve the use of chemotherapy. (1 is no value, 5 is highest value)

highly value the possibility of a CRC treatment that does not involve the use of chemotherapy. (1 is no value, 5 is highest value)

Value of a CRC Treatment Option that Does Not Involve Chemotherapy




### Growing Interest in Immunotherapy

Immunotherapy continues to generate interest as a potential treatment in colorectal cancer.

**79%**

of HCPs see improved overall survival as a potential benefit of new immuno-oncology (IO) therapies.

#### Interest in New Treatment Options Outside of Chemotherapy, Including IOs



**Over 1/2 of Patients** expressed interest in new treatment options beyond chemotherapy



Newer immunotherapy options are what I'm very excited about.

I am excited about use of targeted agents, immunotherapy in CRC treatment.

Incorporation of IO into the neoadjuvant setting.

—HCPs treating CRC

### Patients Prioritize Quality of Life

Beyond survival, patients value treatments that minimize side effects and allow them to maintain their daily lives with fewer disruptions.



**1/3 of Patients** cited minimal impact on quality of life, in addition to extending life, as a top treatment priority.

**65% of Patients** cited side effects of chemotherapy and/or radiation as the most difficult aspect of their cancer journey.



#### What's important in my CRC journey...



Ability to keep quality of life. I want to be able to have stamina and work like I did before cancer.

—Individual living with CRC

## Colorectal Cancer in Focus Methodology


The survey was conducted online in the U.S. from October to December 2024, gathering responses from 126 patients living with CRC and 100 HCPs specializing in the disease.

The HCP survey was fielded via SERMO from October 14–22, 2024, while the patient survey was distributed through SurveyMonkey and StudyKik, with support from Fight Colorectal Cancer and the Colorectal Cancer Alliance.

**100** HCPs surveyed who treat patients with CRC **126** Patients with CRC Treated


### About the HCPs Surveyed

#### Primary Speciality



■ Hematologist Oncs ■ Medical Oncs ■ Radiation Oncs


#### Practice Set Up



■ All Respondents ■ Hematologist Oncs ■ Medical Oncs ■ Radiation Oncs


### About the Patients Surveyed

#### Gender



■ Male ■ Female

#### Stage of CRC at Diagnosis



The insights gathered from patients and healthcare providers underscore the urgent need for access to innovative treatment options in the fight against colorectal cancer. Despite advancements in screening and treatment, current therapies remain ineffective for the majority of patients with CRC, highlighting a significant unmet need. **AgenuS is committed to addressing these challenges and advancing the standard of care for patients with CRC.**

We are grateful to the healthcare providers and individuals living with colorectal cancer who contributed to this report by sharing their insights. Your input is a catalyst to advancing CRC care, and we value it greatly. We would also like to extend our gratitude to Fight Colorectal Cancer and the Colorectal Cancer Alliance who helped support insights gathering through dissemination of the patient survey.